Aegea Medical said last week it tapped former Cardiokinetix prez & CEO Maria Sainz as its new president and chief executive officer, effective immediately. Sainz will replace former CEO Don Gurskis, who has held the corner office since 2013. Gurskis will remain on as member of the Redwood City, Calif.-based company’s executive management team. “Maria is […]
CardioKinetix Inc.
Edwards CFO Ullem: Share buybacks more likely than M&A
CardioKinetix signs option-to-buy agreement with Edwards Lifesciences; raises $50M | Medtech funding for the week of December 8, 2014
CardioKinetix raises $50m, inks buyout deal with Edwards Lifesciences
December 8, 2014 by Val Kennedy
CardioKinetix raises $50m, inks buyout deal with Edwards Lifesciences
CardioKinetix touts early results with Parachute heart implant
Results from the 1st patients treated with CardioKinetix’s Parachute implant suggest that the device may be able to help reshape the heart following a heart attack, improving pumping.
CardioKinetix debuts Parachute device in China
CardioKinetix said its Parachute ventricular partitioning device was used to treat 2 patients in Beijing.
The Parachute device is used to restore damage to the left ventricle after a heart attack by partitioning the space to its usual geometry and function, according to a press release.
CardioKinetix treats 1st Asian patients with Parachute cardiac implant
Four patients in Kuala Lumpur, Malaysia were successfully treated with CardioKinetix’s catheter-based Parachute ventricular partitioning device, the Menlo Park, Calif.-based firm announced late last month.
CardioKinetix closes $23M tranche in $48M Series E round
CardioKinetix said it’s raised $48 million in its Series E round with the closure of a 2nd tranche worth $23 million and plans to use the proceeds to further its Parachute ventricular partitioning device, which is in a pivotal trial.
CardioKinetix lands CE Mark for its full suite of Parachute heart implant sizes
California-based medical device company CardioKinetix landed CE Mark approval in the European Union for the full suite of its Parachute ventricular partitioning devices, including 8 sizes of the device designed to provide support to weakened heart muscles. .
CardioKinetix’s cath-based Parachute may “revolutionize” treatment
CardioKinetix made strides in research for its novel Parachute catheter-based left ventricle implant, which proved promising after 2 years in study results unveiled at this year’s EuroPCR conference in Paris.
The Parachute is inserted into the heart via a catheter threaded through the femoral artery. Once inside the heart, the device springs open and attaches to the walls of the heart to provide support for patients whose left ventricle was left enlarged after a heart attack.
